What PROCEPT BioRobotics does

PROCEPT BioRobotics (NASDAQ: PRCT) is a publicly traded surgical robotics company that develops and commercializes image-guided, robotic-assisted systems for the treatment of benign prostatic hyperplasia (BPH) and, increasingly, prostate cancer. The company's core offering is Aquablation therapy — a heat-free, robotic waterjet procedure that combines real-time transrectal ultrasound imaging, digital cystoscopy, computer-assisted treatment planning, and a robotic effector to execute a surgeon-defined resection contour while preserving critical anatomy (bladder neck, verumontanum, external sphincter) across prostates of 20–242 mL. The technology is delivered through two generations of robotic systems: the legacy AquaBeam (FDA-cleared December 2017) and the next-generation, AI-powered HYDROS (FDA 510(k)-cleared August 2024, CE-marked), which embeds FirstAssist AI for automated treatment planning and a single-use scope to support mass-market adoption.

The business is a razor-and-blade model with two revenue streams: one-time capital equipment sales of HYDROS/AquaBeam systems to hospitals, ambulatory surgery centers, and government hospitals (U.S. HYDROS ASP reached ~$485,000 in Q1 2026) and recurring consumable revenue from single-use handpieces and drapes (~US$3,340 ASP per procedure). PROCEPT sells exclusively through a direct enterprise field-sales motion supported by inside sales and clinical representatives at its San Jose, California headquarters, with an installed base of 765 U.S. systems as of Q1 2026 and ~12,200 U.S. Aquablation procedures performed in the quarter. The company also runs the WATER IV prostate cancer clinical program (WATER IV RP completed enrollment at 280 patients; WATER IV AS FDA IDE-approved for up to 333 patients), positioning Aquablation as a potential therapeutic modality in prostate cancer beyond BPH.

The company is led by CEO Larry L. Wood (formerly of Edwards Lifesciences) since September 2025, with FDA, CE-mark, and country-specific regulatory clearances across eight-plus jurisdictions, and guideline endorsements from the American Urological Association (strong recommendation, May 2026) and European Association of Urology (strong recommendation, March 2026). FY2025 revenue was $308.1M (+37% YoY), Q1 2026 revenue was $83.1M (+20% YoY), and management is guiding FY2026 revenue to $390–$410M with a target of positive adjusted EBITDA by Q4 2026.

Name

PROCEPT BioRobotics

Legal name

PROCEPT BioRobotics Corporation

Website

https://procept-biorobotics.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

501–1,000 employees

Short description

PROCEPT BioRobotics develops and commercializes image-guided, robotic-assisted systems (HYDROS and AquaBeam) that deliver Aquablation therapy — a heat-free waterjet treatment for benign prostatic hyperplasia (BPH) — directly to urologists, hospitals, ambulatory surgery centers, and government hospitals, with a growing international footprint.

Ownership category

akta.pro rank

Product category

Surgical Robotics for Urology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)

akta.pro primary industry

Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)

akta.pro secondary industry

Healthcare & Assistive Robotics (HDAAAIAC)

Keywords

• Surgical robotics
• Urology medical devices
• Benign prostatic hyperplasia treatment
• Robotic-assisted surgery
• Waterjet tissue resection

Headquarters

HQ city

Redwood Shores

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Marketing or Sales, Technology or R&D, Supply Chain, Personnel, Infrastructure

Revenue model

1. Capital equipment sales (robotic systems): One-time sale of AQUABEAM and HYDROS Robotic Systems to hospitals, ambulatory surgery centers, and government hospitals. Q1 2026 sold 49 U.S. HYDROS systems at an all-time high average selling price of approximately $485,000 (14% sequential increase); installed base grew to 765 U.S. systems (up 40% YoY). 2026 system revenue guidance of $95–$100 million with planned placements of 200+ new HYDROS systems.
2. Recurring consumables (handpieces and disposable accessories): Recurring revenue from sale of single-use handpieces, drapes, and disposable kits used per Aquablation procedure. Q3 2025 handpiece and consumable revenue grew 50% YoY to $44.4 million. Q4 2025 handpiece average selling price of approximately $3,340 (5% sequential increase). Approximately 12,200 U.S. procedures performed in Q1 2026, representing the underlying recurring procedure-driven demand.
3. International system sales: International capital sales of HYDROS Robotic Systems, beginning with the UK launch in March 2026 as the first expansion outside the United States. Q1 2026 initiated European expansion with 7 systems sold in the United Kingdom. Further international expansion planned for 2026 across UK, Japan, Korea, and other regions.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels11 records

Core offering

PROCEPT BioRobotics develops and manufactures image-guided, robotic-assisted surgical systems (AquaBeam and HYDROS Robotic Systems) that deliver its proprietary Aquablation therapy — a heat-free waterjet treatment for benign prostatic hyperplasia (BPH). The company generates revenue from one-time capital sales of the robotic systems to hospitals and ambulatory surgery centers, plus recurring per-procedure revenue from single-use handpieces, drapes, and disposable kits. The next-generation HYDROS platform adds the FirstAssist AI software module for AI-powered, patient-unique treatment planning.

Product overview

PROCEPT BioRobotics offers a unified surgical robotics platform for the treatment of benign prostatic hyperplasia (BPH), centered on its proprietary Aquablation therapy. The core product line consists of two generations of robotic delivery systems: the legacy AquaBeam Robotic System and the next-generation, AI-powered HYDROS Robotic System, both of which execute the heat-free, image-guided waterjet Aquablation procedure. The HYDROS platform extends the AquaBeam foundation by integrating FirstAssist AI, an AI-powered treatment planning module that uses advanced image recognition to identify critical anatomy on ultrasound and propose an optimal, patient-unique treatment contour, as well as next-generation ultrasound imaging, digital cystoscopy, and a streamlined workflow. The company is also expanding its clinical footprint beyond BPH with the WATER IV prostate cancer clinical program. The offering is therefore a platform-plus-modules architecture: the underlying therapy (Aquablation), two delivery platforms (AquaBeam and HYDROS), and an embedded AI software module (FirstAssist AI) that enhances personalization on the latest system.

Differentiator

Problem solved

Functional benefit

Brands

• Aquablation Therapy: Image-guided, robotic-assisted, heat-free waterjet therapy for the treatment of benign prostatic hyperplasia (BPH), delivered via the AquaBeam and HYDROS Robotic Systems.
• AquaBeam Robotic System
• HYDROS Robotic System
• FirstAssist AI
• Aquablation (patient website at aquablation.com)

Products and services

• HYDROS Robotic System Next-generation, AI-powered robotic platform for Aquablation therapy to treat BPH. Features FirstAssist AI treatment planning, advanced image guidance (ultrasound plus digital cystoscopy), robotic heat-free waterjet resection, dual high-definition touchscreens, an adjustable touchscreen tower for surgeon ergonomics, and a single-use scope architecture. FDA 510(k)-cleared and CE-marked (CE 2797).
• AquaBeam Robotic System First-generation, advanced image-guided surgical robotic system combining real-time multidimensional imaging, personalized treatment planning, and robotic-assisted heat-free waterjet resection for precise and rapid removal of prostate tissue. The original delivery platform for Aquablation therapy, with an installed base of approximately 200 systems that are candidates for upgrade to HYDROS. FDA-cleared in December 2017.
• Aquablation Therapy The underlying therapy procedure performed by the AquaBeam and HYDROS Robotic Systems. The only image-guided, robotic-assisted, heat-free waterjet treatment for BPH that uses computer-assisted treatment planning to maximize tissue resection while preserving important anatomy (bladder neck, verumontanum, external sphincter) across prostates of all shapes and sizes (20–242 mL). Delivered to hospitals, ambulatory surgery centers, and government hospitals.
• FirstAssist AI AI-powered treatment planning software built from a library of real-world Aquablation therapy procedures. Uses advanced image recognition to identify critical anatomy on intraoperative ultrasound (bladder neck, verumontanum, external sphincter) and suggest an optimal, patient-unique treatment plan. FDA-cleared in second-generation form (Gen-2) in May 2026 for the HYDROS Robotic System.

Quantifiable outcome

• Preservation of ejaculatory function in the majority of treated men (Aquablation therapy's clinical studies) vs. significant rates of ejaculatory dysfunction with TURP
• +8 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

Partnerships

Two partnerships are on record, tiered minor.

• Shockwave MedicalminorOthers · 6 March 2026Shockwave Medical is the prior employer of newly appointed independent director Daniel Puckett (retired as CFO of Shockwave Medical in February 2024). PROCEPT BioRobotics is not a strategic or commercial partner of Shockwave Medical — the connection is a board/talent relationship only.
• Edwards LifesciencesminorOthers · 8 August 2025Edwards Lifesciences is the prior employer of new PROCEPT BioRobotics CEO Larry L. Wood (18-year executive who led the Transcatheter Aortic Valve Replacement division). PROCEPT BioRobotics is not a strategic or commercial partner of Edwards Lifesciences — the connection is a leadership/talent relationship only.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Intuitive Surgical: Developer of the da Vinci surgical robotic platform, the dominant multi-specialty soft-tissue surgical robotics company. Comparable as the leading surgical robotics incumbent against which PRCT's specialty urology robotics platform competes for hospital capital budgets and OR utilization.
• Medtronic: Diversified medical device leader developing the Hugo robotic-assisted surgery platform for urology and other soft-tissue applications. Comparable as a broad incumbent entering surgical robotics for urology, directly competing for the same hospital capital equipment spend.
• Stryker: Medical device leader with the Mako robotic platform for orthopedics and a broader surgical/endoscopy portfolio. Comparable as a NASDAQ-listed broad incumbent in surgical robotics named alongside PRCT in industry analyst reports (Grand View Research).
• Johnson & Johnson (Ethicon / Auris Health): Through Ethicon and Auris Health, J&J is developing the Ottava robotic surgery platform. Comparable as a broad incumbent in surgical robotics targeting the urology specialty, competing for capital equipment budgets.
• Olympus Corporation: Global leader in urology endoscopy and energy-based BPH devices (laser enucleation, bipolar resection). Comparable as a broad incumbent in urological surgery equipment that competes for the same urology capital equipment and procedure share.
• Zimmer Biomet: Developer of the ROSA robotic surgery platform. Comparable as a NASDAQ-listed broad incumbent in surgical robotics named alongside PRCT in industry analyst reports.
• Smith+Nephew: Developer of the CORI robotic-assisted surgical system for orthopedics. Comparable as a broad incumbent in surgical robotics named alongside PRCT in industry analyst reports and competing for hospital robotics capital budgets.

Direct peers

• Boston Scientific: Markets the Rezūm water-vapor thermal therapy system and other BPH/urology devices. Comparable as a direct competitor in the BPH surgical treatment market, targeting the same urology customers with an alternative minimally invasive BPH modality.
• Teleflex: Markets the Urolift System, a leading minimally invasive BPH treatment competing head-to-head with Aquablation. Comparable as a direct competitor in the office/outpatient BPH procedure market that PRCT is also targeting with ambulatory surgery center adoption.

Regional players

• Karl Storz: Privately held German leader in urological endoscopy and visualization, with a strong installed base in European hospitals. Comparable as a regional incumbent in urology visualization/resection equipment that competes for the same urology OR share as PRCT's HYDROS platform, particularly relevant to PRCT's European expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/PROCEPTRobotics
• Facebookfacebook.com/PROCEPTBioRobotics
• LinkedInlinkedin.com/company/procept-corporation

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PROCEPT BioRobotics